Clinical Trials Logo

Filter by:
NCT ID: NCT06297941 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study of REM-422 in Patients With AML or Higher Risk MDS

Start date: April 26, 2024
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

NCT ID: NCT06297876 Recruiting - Vaccine Hesitancy Clinical Trials

COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color

Start date: May 19, 2023
Phase: N/A
Study type: Interventional

Pilot randomized controlled trial testing the investigator's previously developed storytelling method to create an interactive, multi-media storytelling intervention to address community-identified reasons for vaccine hesitancy among Black and Hispanic individuals in Central Massachusetts

NCT ID: NCT06297603 Recruiting - Type 2 Diabetes Clinical Trials

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Start date: March 15, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

NCT ID: NCT06297551 Recruiting - Clinical trials for Acute Myeloid Leukemia

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

Start date: March 5, 2024
Phase:
Study type: Observational

Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow and the most common form of acute leukemia in adults. Patient with AML have the shortest survival compared to other forms of leukemia. In the past 6 years, several new therapies have been approved. Biomarkers are in urgent need to guide therapeutic regimen selection in order to maximize the benefit of available therapies and minimize treatment toxicity. Current standard practice is to perform bone marrow biopsy at end of treatment cycle (each cycle around 28 days), and based on bone marrow finding, to decide further treatment plan. It is invasive and time consuming. The research we are proposing here is to investigate whether tracking leukemia stem cells (LSC) in peripheral blood during early treatment cycle may provide a non-invasive method to predict therapeutic outcome at end of treatment cycle. Our retrospective study have found that LSC fractional change, defined by two LSC markers, named CLL1 and CD45RA, is highly correlated with therapeutic outcome. Further more, CLL1 and CD45RA positive LSC fraction demonstrates a high concordance between bone marrow and peripheral blood, offering the opportunity to track CLL1 and CD45RA positive LSC fraction non-invasively in peripheral blood during treatment. This pilot study will allow us to decide whether testing CLL1 and CD45RA positive LSC in peripheral blood during leukemia treatment is feasible in clinical practice. This result will lay the foundation for designing future trials using CLL1 and CD45RA positive LSC fractional change to optimize therapeutic strategy for patients with AML.

NCT ID: NCT06297486 Recruiting - Hemophilia A Clinical Trials

Study of a Gene Therapy Treatment for Hemophilia A

KEYSTONE 1
Start date: March 13, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of SPK-8011 in preventing bleed episodes compared with FVIII prophylaxis in participants with hemophilia A without FVIII inhibitors on routine FVIII prophylaxis.

NCT ID: NCT06297278 Recruiting - Adolescence Clinical Trials

Exercise Facilitation of Adolescent Fear Extinction, Frontolimbic Circuitry, and Endocannabinoids

BRAINS
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Anxiety disorders commonly begin during adolescence, and are characterized by deficits in the ability to inhibit or extinguish pathological fear. Recent research has provided new understanding of how fear is learned and can be regulated in the adolescent brain, and how the endocannabinoid system shapes these processes; however, these advances have not yet translated into improved therapeutic outcomes for adolescents with anxiety. This study will test whether a behavioral intervention, acute exercise, can help to improve fear regulation by enhancing brain activity and endocannabinoid signaling. This line of research may ultimately lead to more effect treatments for adolescent anxiety, and to new preventive strategies for at-risk youth.

NCT ID: NCT06297226 Recruiting - Multiple Myeloma Clinical Trials

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

QUINTESSENTIAL
Start date: March 21, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

NCT ID: NCT06297070 Recruiting - Fertility Issues Clinical Trials

Lifestyle Care for Fertility Outcome Evaluation

PROWESS
Start date: January 24, 2024
Phase:
Study type: Observational

An observational outcome evaluation of the Lifestyle Care for Fertility program.

NCT ID: NCT06296966 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Start date: February 29, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

NCT ID: NCT06296940 Recruiting - Clinical trials for Posttraumatic Stress Disorder

Written Exposure in Substance Treatment

WEST
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this pilot randomized clinical trial is to test the feasibility and efficacy of written exposure therapy (WET) for posttraumatic stress disorder (PTSD) within the context of residential substance use disorder (SUD) treatment. All participants meet criteria for PTSD and are in a short term residential SUD treatment program (target residential treatment duration = 28 days) regardless of the research. The main questions the study aims to answer are: 1) Is the delivery of WET feasible in short term residential SUD treatment for individuals with severe SUD; 2) Do participants in the TAU+WET condition have greater reductions in PTSD symptoms pre/post treatment compared to participants in TAU alone?